Effect L-Arginine and intravenous fluid Therapy in Oligohydramnios

Comparison of Effect L-Arginine and intravenous fluid Therapy in Oligohydramnios

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160523028008N5

Enrollment

Registered

2020-12-15

Start date

2020-05-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligohydramnios. Oligohydramnios

Interventions

Intervention 1: Intervention group: L-arginine at a dose of 3 grams twice a day with oral fluid therapy or, if possible (not suffering from gestational hypertension), 3 liters of inject able lactate r

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Gestational age between 28 and 36 weeks Single pregnancy AFI less than 8 cm

Exclusion criteria

Exclusion criteria: Pregnancy with anomalies Diabetes Severe preeclampsia Preterm Premature Rupture of Membranes (PPROM)

Design outcomes

Primary

Measure	Time frame
Amniotic fluid index. Timepoint: One week after the intervention for up to 4 weeks. Method of measurement: Ultrasonography.	—

Secondary

Measure	Time frame
Neonatal Apgar score. Timepoint: At 1 and 5 minutes after birth. Method of measurement: Data sheets.;Neonatal weight. Timepoint: At birth. Method of measurement: Data sheets, gram.;Gestational Age at birth. Timepoint: At the end of the study. Method of measurement: Data sheets.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahla Nasrolahi

Hamedan University of Medical Sciences

Dr-nasrolahi@yahoo.com+98 81 3838 0717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026